These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 23697926)

  • 21. Zr-89 Immuno-PET Targeting Ectopic ATP Synthase Enables In-Vivo Imaging of Tumor Angiogenesis.
    Park BN; Kim GH; Ko SA; Shin GH; Lee SJ; An YS; Yoon JK
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model.
    Muselaers CH; Oosterwijk E; Bos DL; Oyen WJ; Mulders PF; Boerman OC
    Mol Imaging; 2014; 13():1-7. PubMed ID: 24824962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody.
    Knowles SM; Zettlitz KA; Tavaré R; Rochefort MM; Salazar FB; Stout DB; Yazaki PJ; Reiter RE; Wu AM
    J Nucl Med; 2014 Mar; 55(3):452-9. PubMed ID: 24504052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.
    Oosterwijk-Wakka JC; Kats-Ugurlu G; Leenders WP; Kiemeney LA; Old LJ; Mulders PF; Oosterwijk E
    BJU Int; 2011 Jan; 107(1):118-25. PubMed ID: 20346054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116.
    Terwisscha van Scheltinga AG; Lub-de Hooge MN; Abiraj K; Schröder CP; Pot L; Bossenmaier B; Thomas M; Hölzlwimmer G; Friess T; Kosterink JG; de Vries EG
    MAbs; 2014; 6(4):1051-8. PubMed ID: 24870719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts.
    Cheal SM; Ruan S; Veach DR; Longo VA; Punzalan BJ; Wu J; Fung EK; Kelly MP; Kirshner JR; Giurleo JT; Ehrlich G; Han AQ; Thurston G; Olson WC; Zanzonico PB; Larson SM; Carrasquillo JA
    Mol Pharm; 2018 Jun; 15(6):2133-2141. PubMed ID: 29684277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor.
    Yang X; Minn I; Rowe SP; Banerjee SR; Gorin MA; Brummet M; Lee HS; Koo SM; Sysa-Shah P; Mease RC; Nimmagadda S; Allaf ME; Pomper MG
    Oncotarget; 2015 Oct; 6(32):33733-42. PubMed ID: 26418876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250.
    Steffens MG; Boerman OC; Oosterwijk-Wakka JC; Oosterhof GO; Witjes JA; Koenders EB; Oyen WJ; Buijs WC; Debruyne FM; Corstens FH; Oosterwijk E
    J Clin Oncol; 1997 Apr; 15(4):1529-37. PubMed ID: 9193349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study.
    Hekman MC; Boerman OC; de Weijert M; Bos DL; Oosterwijk E; Langenhuijsen JF; Mulders PF; Rijpkema M
    Clin Cancer Res; 2016 Sep; 22(18):4634-42. PubMed ID: 27103404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radionuclide and Fluorescence Imaging of Clear Cell Renal Cell Carcinoma Using Dual Labeled Anti-Carbonic Anhydrase IX Antibody G250.
    Muselaers CH; Rijpkema M; Bos DL; Langenhuijsen JF; Oyen WJ; Mulders PF; Oosterwijk E; Boerman OC
    J Urol; 2015 Aug; 194(2):532-8. PubMed ID: 25686542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.
    Davis ID; Liu Z; Saunders W; Lee FT; Spirkoska V; Hopkins W; Smyth FE; Chong G; Papenfuss AT; Chappell B; Poon A; Saunder TH; Hoffman EW; Old LJ; Scott AM
    Cancer Immun; 2007 Aug; 7():14. PubMed ID: 17705350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.
    Davis ID; Wiseman GA; Lee FT; Gansen DN; Hopkins W; Papenfuss AT; Liu Z; Moynihan TJ; Croghan GA; Adjei AA; Hoffman EW; Ingle JN; Old LJ; Scott AM
    Cancer Immun; 2007 Aug; 7():13. PubMed ID: 17705349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250.
    Pryma DA; O'Donoghue JA; Humm JL; Jungbluth AA; Old LJ; Larson SM; Divgi CR
    J Nucl Med; 2011 Apr; 52(4):535-40. PubMed ID: 21421715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma.
    Oosterwijk-Wakka JC; Boerman OC; Mulders PF; Oosterwijk E
    Int J Mol Sci; 2013 May; 14(6):11402-23. PubMed ID: 23759990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.
    Turkbey B; Lindenberg ML; Adler S; Kurdziel KA; McKinney YL; Weaver J; Vocke CD; Anver M; Bratslavsky G; Eclarinal P; Kwarteng G; Lin FI; Yaqub-Ogun N; Merino MJ; Linehan WM; Choyke PL; Metwalli AR
    Abdom Radiol (NY); 2016 Jan; 41(1):109-18. PubMed ID: 26830617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.
    Holland JP; Divilov V; Bander NH; Smith-Jones PM; Larson SM; Lewis JS
    J Nucl Med; 2010 Aug; 51(8):1293-300. PubMed ID: 20660376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ImmunoPET imaging of tissue factor expression in pancreatic cancer with
    Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W
    J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with
    Yoon JT; Longtine MS; Marquez-Nostra BV; Wahl RL
    J Nucl Med; 2018 Aug; 59(8):1219-1224. PubMed ID: 29348316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.
    Sharma SK; Sevak KK; Monette S; Carlin SD; Knight JC; Wuest FR; Sala E; Zeglis BM; Lewis JS
    J Nucl Med; 2016 May; 57(5):771-6. PubMed ID: 26837339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.